Wellington Management Group LLP Acquires 57,956 Shares of argenx SE (NASDAQ:ARGX)

Wellington Management Group LLP raised its holdings in argenx SE (NASDAQ:ARGX) by 26.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 279,168 shares of the company’s stock after buying an additional 57,956 shares during the period. Wellington Management Group LLP owned about 0.47% of argenx worth $106,204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in ARGX. Parkside Financial Bank & Trust bought a new position in shares of argenx in the third quarter valued at $28,000. FNY Investment Advisers LLC bought a new position in shares of argenx in the fourth quarter valued at $38,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of argenx in the fourth quarter valued at about $60,000. Principal Securities Inc. purchased a new stake in shares of argenx in the fourth quarter valued at about $99,000. Finally, Toronto Dominion Bank raised its holdings in shares of argenx by 174.2% in the third quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock valued at $131,000 after purchasing an additional 169 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Up 2.6 %

Shares of NASDAQ:ARGX opened at $387.87 on Friday. The company has a 50-day moving average price of $375.02 and a two-hundred day moving average price of $388.00. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76. The firm has a market capitalization of $23.05 billion, a PE ratio of -68.53 and a beta of 0.65.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. The firm had revenue of $412.51 million during the quarter, compared to the consensus estimate of $404.03 million. During the same quarter last year, the business posted ($0.52) earnings per share. Analysts anticipate that argenx SE will post -2.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several analyst reports. Truist Financial increased their target price on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. William Blair reiterated a “market perform” rating on shares of argenx in a report on Monday. Morgan Stanley lowered their target price on shares of argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a report on Tuesday, May 28th. Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $448.00 target price on shares of argenx in a report on Friday, June 14th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $520.68.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.